● Introductory pricing is $399 per month for unlimited use and unlimited users. Or you can use the device for up to five patients per month for $199 per month. There is also a one-time device activation fee of $199, regardless of which of these two options you choose.

● We have purposely designed our device to be both affordable and accessible to the greatest number of physicians by making it available on a monthly rental basis, so you avoid the expense of an upfront capital cost while being able to choose from different monthly rental packages based on your anticipated use of the proprietary device and FDA-cleared algorithm. Furthermore, our monthly rental gives you access to a world of additional benefits, such as software updates, customer support, replacement devices in the event of device failure, cloud storage for device results, remote device monitoring by DermaSensor, access to webinars and publications, and more.

● We don’t have a published price for an outright purchase, but we can explore options. Please contact sales at sales@dermasensor.com or call us at +1-855-373-6767

The use of the DermaSensor device is not described by a specific CPT code. The use of DermaSensor may contribute to the work performed during an evaluation and management (E/M) service, as described below. Alternatively, the physician may consider it appropriate to report use of DermaSensor under an unlisted code. New services may be considered experimental or investigational and, therefore, be non-covered by some payers. Patients may choose to receive a non-covered service and pay separately for that service. Physicians should follow payer guidance to appropriately document a patient’s decision to pay separately for such services. For detailed information, we can provide you with a coding guidance document for your review. if you contact sales at sales@dermasensor.com or call us at +1-855-373-6767

DermaSensor offers a 90-day risk-free program for its customers, so your device use agreement allows you to terminate the contract and return the device at any point after the first three months of use. So, the only financial commitment you make when you sign up as a customer is just three months of use. 

We offer on-demand customer support.

We have ongoing clinical trials and also a process to support trials that you may be interested in pursuing. If you’d like to discuss any of these further, then please contact medical affairs at medaffairs@dermasensor.com 

No certification is required to use DermaSensor. Instruction and education on proper usage and handling are fully covered in the Instructions For Use that is included in the device packaging and can be provided by our commercial team. Supplemental educational materials (e.g. Quick Reference Guide, videos, and patient education materials) are also available to all customers.

No. We locked the algorithm, per FDA requirements, and validated the performance through multiple prospective clinical studies. We plan to revalidate and periodically update the algorithm every couple of years, as we have to resubmit to the FDA and get clearance every time the algorithm is updated or new algorithms are added.

No, the device does not provide an output that differentiates between a BCC, SCC, or melanoma when signs of malignancy are present. It will provide the objective output of “Investigate Further” with a scale of 1-10 to indicate the degree of similarity to malignant lesions. The likelihood that a positive “Investigate Further” result is cancerous ranged from 6% for a score of 1 to 61% for a score of 10 in the DERM-SUCCESS FDA Pivotal Clinical Study with over 1,000 patients.

Not presently, but we will certainly be integrating with EHRs over time, depending on device usage and integration needs by users with certain EHRs and at certain health systems. In the meantime, clinicians document the device use and result by simply typing in two things to the EHR for the given patient, similar to adding a patient’s blood pressure result: the 0-10 device result and the unique device number provided for each lesion. Another option that many customers have been implementing is taking a photo of the device result screen with EHR photo apps. A third option is to log in to the DermaSensor web portal, export a PDF of the device result, and attach it to the patient’s EHR record.

The company is actively developing and reviewing with FDA plans for enhanced algorithms and also plans to develop a next-generation device that includes a camera and other features, but none of this is currently available for use in the clinic at this time.